In high-level reshuffle, Roche gives James Sabry the global reins on deal-making — overseeing pRED and gRED
In the 9 years since Roche bought up all of Genentech, the Swiss pharma giant has been careful to leave its legacy R&D group pRED separate from the folks at the gRED operations they acquired in San Francisco. But in a startling shift today the executive team knitted the two groups’ BD teams into one, combining partnering ops and making Genentech’s James Sabry their global deal czar for pharma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.